Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic

J Med Virol. 2021 Feb;93(2):714-716. doi: 10.1002/jmv.26528. Epub 2020 Oct 5.
No abstract available

Publication types

  • Letter
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Azetidines / therapeutic use
  • Biological Products / adverse effects
  • Biological Products / therapeutic use*
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • Humans
  • Interleukins / antagonists & inhibitors*
  • Janus Kinase Inhibitors / therapeutic use
  • Purines / therapeutic use
  • Pyrazoles / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sulfonamides / therapeutic use
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal
  • Azetidines
  • Biological Products
  • Interleukins
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • Sulfonamides
  • Tumor Necrosis Factor-alpha
  • baricitinib